Abstract:More and more papers about pharmacoeconomics and outcome research were published in China. The aim of this study was to evaluate the quality of Chinese pharmacoeconomics study and outcome research through analyze papers published in the peer-reviewed literature in Chinese over the last five years. We conducted full-text paper searches in public databases from 2009 to 2013 in China. A search strategy and inclusion criteria were set up to identify the articles to be included. The search identified 820 studies, of which 411 were included. Then papers were evaluated through a framework which was based on Pharmacoeconomics guideline. Our results showed that a large number of published studies were of suboptimal quality. Most of pharmaceonomics and outcome research were conduct by doctors (33.6%) and pharmacists (54%) in China. Prospective studies (65.9%) were the most common study design, while most data were derived from the clinical trials; Only 8% of them included articles clearly stated the study perspective; More than half studies (56.2%) only computed drug expenditure in cost estimation; 2.2% of articles conducted discounting; 63.5% of studies performed the incremental analysis, however, most studies presented the cost-effectiveness ratios as incremental cost-effectiveness ratio; Sensitive analysis were reported by 71.3% of the included studies, nonetheless, the choice of variables for sensitivity analysis wasn’t justified; A few studies (7.3%) presented the transferability of the results. The above data signify that the quality of pharmacoeconomic evaluations needs improvement. There were just few studies which had well-designed schemes, high-qualified data and suitable methodology, partly owing to the doctors and pharmacists’ lack of pharmaceonomics expertise and knowledge. It implied China should improve the training of pharmaceonomics and outcome research training in doctors and pharmacists. Moreover, a further study of the new technology on pharmacoeconomy should not be neglected.

Preliminary Study on Pharmacoeconomics of Adverse Drug Reactions

Causality Assessment of Adverse Drug Reactions and Its Guiding Significance for Post-evaluation of Chinese Patent Medicine

A Critical Review of Chinese Pharmacoeconomics Studies in the Last Five Years.

Study of the Related Problems in the Application of the Cost- Effectiveness Analysis in Pharmacoeconomics

Literature Analysis on Adverse Drug Reaction in China

Analysis of 172 Samples Reported and Discussion about the Methods of Prevention with Adverse Drug Reactions

Epidemic Characteristics of Pharmacoconomic Research in China

An Investigation into Socio-economic Impact of Adverse Drug Reactions of Antibacterial Agent Irrational Use

Bibliometric Analysis of Foreign Pharmacoeconomic Literatures

Analysis on 342 Repors and Discssion about the Methods of Prevention with Adverse Drug Reactions/events

Analysis of Adverse Drug Reactions in 468 Cases

The Application of Pharmacoeconomics in Clinical Medicine Decision Making

Monitoring and Application of ADRs Reports in China

Bibliographic Analysis of Anesthetic Adverse Drug Reactions in China

Application of Path Analysis in Pharmacoeconomics

Research Advances in Pharmacogenetics and Adverse Drug Reactions

Retrospective Analysis of ADR Cases Reported in 2006 in Shenzhen

Pharmacoeconomic Research on Adverse Drug Reactions of Chemotherapy for Lung Cancer

Study on 990 Cases of Adverse Drug Reaction

Analysis of 136 ADRs Induced by Chinese Patent Medicine